Search results
Chart Review Highlights Unique AD Features in Older Patients
Medscape· 2 days agoMore research is "needed to elucidate the unique features of elderly AD in pathophysiology and...
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
Morningstar· 6 days agoJohnson & Johnson has agreed to buy privately-held biotechnology company Proteologix for an initial $850 million in cash in a deal that bolsters the healthcare giant's dermatology portfolio.
Earnings call: Arcutis Biotherapeutics reports strong Q1 2024 growth By Investing.com
Investing.com· 7 days agoArcutis Biotherapeutics (NASDAQ:ARQT) has announced robust financial results for the first quarter...
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Benzinga via AOL· 5 days agoProteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is...
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 7 days agoArcutis Biotherapeutics Inc (NASDAQ:ARQT) is poised for potential market expansion with the upcoming FDA PDUFA target date for its sNDA for atopic dermatitis</ ...
Got Tiny Blood Vessels on Your Face? Here's Why, and How To Treat Them
Well and Good· 7 hours agoMore often than not, those red, spider-like clusters are just...broken blood vessels. Broken blood...
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks· 5 days agoBayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
What to do about rashes on skin
Rolling Out· 5 days agoRashes on the body can be both uncomfortable and concerning, affecting people of all ages and backgrounds. These skin irritations may range from mild
Lipase-mediated detoxification of host-derived antimicrobial fatty acids by Staphylococcus aureus -...
Nature· 7 days agoThis study on how Staphylococcus aureus manipulates host-derived fatty acids reveals that a bacteriallipase (Lip2) converts toxic fatty acids and cholesterol into innocuous cholesteryl esters.
How Does Incyte Stock’s Decline During The 2022 Inflation Shock Compare With The 2008 Crash?
Forbes· 7 days agoINCY stock was trading at around $76 in early June 2022, just before the Fed started increasing...